Effects of 131 I treatment on the circulating granulocyte colony-stimulating factor and leucocyte levels in patients with Graves' disease
0
Citation
0
Reference
20
Related Paper
Abstract:
Objective To observe the effects of 131I treatment on circulating granulocyte colonystimulating factor (G-CSF) and leucocyte levels of patients with Graves' disease (GD).Methods Enzyme-linked immunosorbent assay (ELISA),coulter three assortments,and radioimmunoassay were used to test the levels of circulating G-CSF,leucocytes and thyroid hormones of 65 incipient and untreated GD patients,all females,aged 21 -50,43 with normal leucocyte level and 22 with leucopenia before and after 131I treatment.Thirty age-matched healthy female subjects were used as controls.Results Before 131I treatment,the serous G-CSF level of the GD patients with normal leucocyte level was (28.4 ± 11.7)μg/L,significantly higher than that of the control [ ( 18.3 ± 6.98) μg/L,t =2.376,P ＜ 0.05 ].The serous G-CSF level of the GD patients with leucopenia was (40.1 ± 13.8 ) μg/L,significantly higher than that of the patients with normal leucocyte level ( t =2.788,P ＜ 0.01 ) and that of the control ( t =3.672,P＜0.01 ).180 d after the initiation of 131 I treatment,the G-CSF level of the patients with normal leucocyte level was (18.9 ± 8.32) μg/L,not significantly different from that of the normal controls,however,the G-CSF level of the GD patients with leucopenia was (25.7 ± 11.5) μg/L,still significantly higher than that of the normal control (t =2.103,P ＜ 0.05).The serous G-CSF level was negatively correlated with the titer of leucocyte ( r =- 0.38,P ＜ 0.05 ),however,not significantly correlated with such clinical parameters,as free triiodothyronine (FT3),free thyroxine (FT4) and thyrotropin-stimulating hormone (TSH).Conclusions Abnormal increment of G-CSF is observed in the GD patients,which may be related to the decrease of leucocyte.Effectively suppressing the auto-immune status in the GD patients,131I treatment is a safe and reliable therapy for GD patients with leucopenia and should be used as early as possible.
Key words:
Graves' disease ; Granulocyte colony-stimulating factor; Leucopenia ; 131 I treatmentAbstract Introduction Immune cells and molecules are considered as clinical biomarkers and potential targets for immunotherapy. Analyses of the composition of peripheral blood cells hold promise for providing a basis for diagnosing and prognosis lung cancer. In this study, we assessed correlations between immune cell subset profiles in peripheral blood and disease prognosis in patients with lung cancer. Methods One hundred and thirteen patients with lung cancer and 99 age‐matched healthy people were enrolled in this study. The percentage and cell count of monocytes, neutrophils, T cells, B cells, natural killer (NK), and NKT cells in peripheral blood were analyzed by flow cytometry or peripheral blood analyzer. Serum cytokines and colony‐stimulating factors were detected by enzyme‐linked immunosorbent assay (ELISA). Results A reduction in antitumor NK cells ( p < 0.0001) and an increase in the protumor MDSCs ( p < 0.0001) were observed in the lung cancer patients compared with the controls. Monocyte counts were significantly higher in lung cancer patients with histories of smoking ( p < 0.05) or drinking ( p < 0.01) than in patients with no relevant history or healthy controls. The number of neutrophils and the neutrophil‐to‐lymphocyte ratio (NLR) were particularly higher in patients with liver metastasis ( p < 0.01) compared with no metastasis patients or healthy controls. Levels of the monocyte‐derived cytokine interleukin‐6 ( p < 0.05), granulocyte colony‐stimulating factor (G‐CSF) ( p < 0.0001), and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) ( p < 0.0001) were higher in patients than in controls. G‐CSF levels decreased during the remission phase ( p < 0.05), and positively correlated with carbohydrate antigen 19–9 ( p < 0.05) and gene mutation ( p < 0.05). Conclusion Monocyte and neutrophil counts were higher in peripheral blood in lung cancer patients than in controls, especially when patients had histories of smoking, drinking, and liver metastasis. Serum levels of G‐CSF and GM‐CSF were higher in lung cancer patients, and G‐CSF levels positively correlated with disease severity.
Monocyte
Cite
Citations (14)
Objective: To observe the expression of Granulocyte clony-stimulating factor (G-CSF) and its receptor(G-CSFR)in peripheral blood of patients with hyperthyroidism and explore its clinical significance. Methods: Fourty-three normal controls, 63 novel patients of hyperthyroidism and 22 patients with antithyroid drug.(ATD) therapy were investigated with enzyme-linked immunosorbent assay(ELISA), monoclonal antibody and flow cytometry, the relationship between the expression of G-CSF,G-CSFR level and granulocyte in peripheral blood were analyzed. Results: There were no significant differences in G-CSFR expression rates, numbers of leukocyte and neutrophil between three groups(P 0.05). The Levels of G-CSF in serum of patients with hyperthyroidism was significantly higher than that of normal control (novel group P 0.01,ATD therapy group P 0.05). There was no significant correlation in G-CSFR expression rate and G-CSF levels with number of neutrophil between all groups(P 0.05). Conclusion: The Levels of G-CSF in peripheral blood increased in patients with hyperthyroidism. These results may be related to immune response.
Clinical Significance
Cite
Citations (0)
We have investigated the plasma levels of G-CSF and M-CSF and commonly accepted tumor marker CA 15-3 in 54 breast cancer patients before and after surgery and chemotherapy. The patients were divided into two groups: A (stage I) and B (stage II). G-CSF i M-CSF were determined using enzyme-linked immunosorbent assay (ELISA), CA 15-3 was measured by microparticle enzyme immunoassay (MEIA). G-CSF and M-CSF plasma levels (similarly as CA 15-3) were significantly higher in breast cancer patients before surgery comparing to the control group. After surgery plasma level of G-CSF (as CA 15-3) was decreased, but M-CSF increased. The plasma levels of tested cytokines and CA 15-3 increased after chemotherapy. This study suggests that tested cytokines (especially G-CSF) can be clinically useful in diagnostics of breast cancer, yet further investigation and confirmation by a prospective study are necessary.
CA 15-3
Cite
Citations (3)
Colony-stimulating factor
Cite
Citations (4)
Chronic renal failure
Cite
Citations (15)
The granulocyte colony-stimulating factor (G-CSF) is the most commonly used hematopoietic growth factor recombinant DNA technology. It affects bone metabolism by modulating both osteoclast and osteoblast functions. The aim of the present study was to investigate the effects of short-term use of G-CSF on bone metabolism in children with leukemia and solid tumors.Thirty-six patients with a malignancy who received G-CSF therapy according to chemotherapy protocols and another 20 growth factor-free cancer patients who were enrolled as controls were included in the study. The serum osteocalcin and urinary free deoxypyridinoline levels were measured before the start of G-CSF therapy, on day 3 after treatment, and 7 days after G-CSF therapy was discontinued. In the control group, the measurements were made during corticosteroid and methotrexate-free chemotherapy.The mean osteocalcin level (8.6±2.3 ng/mL) from before the onset of treatment decreased significantly (7.7±2.3 ng/mL) on day 3 of G-CSF therapy and significantly increased after 7 days of G-CSF therapy (7.9±2.2 ng/mL) (p<0.001 and p<0.001, respectively), which was still significantly lower than the pre-G-CSF values (p<0.001). The urinary free deoxypyridinoline level significantly increased on day 3 of G-CSF treatment (25.6±6.5 nmol/mmol Cr) and significantly decreased after 7 days of G-CSF therapy (22.6±6.4 nmol/mmol Cr) (p<0.001 and p<0.001, respectively), which was still significantly higher than the values recorded before G-CSF therapy (p<0.001).The findings show that the short-term use of G-CSF in children with cancer can affect bone metabolism and can play a role in metabolic changes. Decreased osteoblastic activity and increased osteoclastic activity suggest that osteoporosis may be associated with bone pain in these patients.
Deoxypyridinoline
Bone remodeling
Hematopoietic growth factor
Cite
Citations (3)
To investigate the effects of serum component from patients with Graves's disease (GD) on the growth of colony forming unit-granulocyte monocyte (GM-CFU).Monocytes were obtained from 11 normal persons and 11 GD patients with leukopenia and culture together with sera from 11 GD patients with leukopenia, 11 GD patients without leukopenia, and 11 normal controls for 10 days. Inverted microscopy was used to count the number of colony.Thyroid stimulating immunoglobulin (TSI) and serum from GD patients with leukopenia significantly inhibited the formation of GM-CFU (P < 0.01) while methimazole, thyroxine and serum from GD patients without leukopenia did not have any effect on the formation of GFU-GM (P > 0.05).TSI and serum from GD patients with leukopenia remarkably inhibit GM-CFU growth. Autoimmune abnormality may play an important role in the pathogenesis of leukopenia in patients with GD.
Leukopenia
Monocyte
Pathogenesis
Cite
Citations (0)
Leukopenia
Mitomycin C
Leukocytosis
Cite
Citations (10)
Despite the fact that granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are increasingly used in clinical practice, little is known of their endogenous production, especially in myeloproliferative disorders such as chronic myelogenous leukemia (CML).In order to define serum levels of GM-CSF and G-CSF in subjects affected by CML, the sera of 17 patients with CML in chronic phase treated either with hydroxyurea or interferon-alpha were tested by specific enzyme immunoassays. Fifteen age- and sex-matched healthy volunteers were used as normal controls.Eight out of the 17 patients (44%) with CML showed detectable (> 3 pg/mL) serum levels of GM-CSF (range 3.9-55 pg/mL). Detectable levels (> 50 pg/mL) of G-CSF were observed in 9 of these patients (52%) (range 150-2,830 pg/mL). On the contrary, among the normal controls only one had detectable GM-CSF concentrations, and none had detectable G-CSF concentrations. The highest concentrations of both GM-CSF and G-CSF were seen in patients with the highest white blood cell counts, although a linear correlation between the levels of these growth factors and the number of circulating leukocytes was not demonstrated.Our data indicate that significant amounts of both endogenous GM-CSF and G-CSF are detectable in the serum of a substantial percentage of patients with CML in chronic phase. The pathophysiological meaning of this finding remains to be determined.
Chronic myelogenous leukemia
Colony-stimulating factor
Myeloproliferative Disorders
White blood cell
Cite
Citations (15)